Trefoil Therapeutics is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop regenerative pharmacologic treatments for corneal diseases. Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. The company's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.